Y-mAbs Therapeutics (NASDAQ:YMAB) Trading Up 6.3% – What’s Next?

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)’s stock price shot up 6.3% during trading on Wednesday . The stock traded as high as $11.48 and last traded at $11.45. 45,696 shares were traded during mid-day trading, a decline of 86% from the average session volume of 327,551 shares. The stock had previously closed at $10.77.

Wall Street Analysts Forecast Growth

YMAB has been the subject of several analyst reports. Wedbush reiterated an “outperform” rating and set a $23.00 price objective on shares of Y-mAbs Therapeutics in a research report on Tuesday, September 10th. Canaccord Genuity Group reissued a “buy” rating and set a $26.00 price target on shares of Y-mAbs Therapeutics in a report on Tuesday, August 13th. HC Wainwright reaffirmed a “buy” rating and issued a $22.00 price objective on shares of Y-mAbs Therapeutics in a report on Friday, November 15th. Canaccord Genuity Group raised shares of Y-mAbs Therapeutics to a “strong-buy” rating in a research note on Tuesday, August 13th. Finally, Oppenheimer assumed coverage on shares of Y-mAbs Therapeutics in a report on Monday, November 18th. They issued an “outperform” rating and a $23.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $21.38.

Y-mAbs Therapeutics Trading Up 10.1 %

The company’s 50-day moving average is $13.57 and its 200 day moving average is $12.82. The firm has a market cap of $531.20 million, a PE ratio of -21.20 and a beta of 0.68.

Y-mAbs Therapeutics (NASDAQ:YMAB) last issued its earnings results on Friday, November 8th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.02). The business had revenue of $18.46 million during the quarter, compared to analyst estimates of $23.38 million. Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. During the same period last year, the business earned ($0.18) EPS. On average, research analysts predict that Y-mAbs Therapeutics, Inc. will post -0.64 EPS for the current fiscal year.

Insider Activity

In other Y-mAbs Therapeutics news, insider Thomas Gad sold 30,000 shares of Y-mAbs Therapeutics stock in a transaction on Monday, September 16th. The shares were sold at an average price of $12.97, for a total transaction of $389,100.00. Following the completion of the sale, the insider now owns 67,681 shares of the company’s stock, valued at $877,822.57. This trade represents a 30.71 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. 22.50% of the stock is owned by corporate insiders.

Institutional Trading of Y-mAbs Therapeutics

Institutional investors have recently bought and sold shares of the company. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in Y-mAbs Therapeutics in the 3rd quarter worth about $44,000. China Universal Asset Management Co. Ltd. grew its stake in shares of Y-mAbs Therapeutics by 66.3% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,572 shares of the company’s stock valued at $113,000 after buying an additional 3,416 shares in the last quarter. Intech Investment Management LLC acquired a new position in Y-mAbs Therapeutics in the third quarter worth approximately $133,000. SG Americas Securities LLC acquired a new stake in Y-mAbs Therapeutics in the third quarter valued at approximately $178,000. Finally, Empire Financial Management Company LLC acquired a new position in shares of Y-mAbs Therapeutics during the 3rd quarter worth $210,000. Institutional investors and hedge funds own 70.85% of the company’s stock.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.